Sarepta Therapeutics, Inc. Earnings

Sarepta Therapeutics, Inc.’s revenue jumped 68.38% since last year same period to $611.09Mn in the Q2 2025. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated -17.96% fall in its revenue since last 3-months.

Sarepta Therapeutics, Inc.’s net profit jumped 2947.86% since last year same period to $196.89Mn in the Q2 2025. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated 144% jump in its net profits since last 3-months.

Sarepta Therapeutics, Inc.’s net profit margin jumped 1710.15% since last year same period to 32.22% in the Q2 2025. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated 153.63% jump in its net profit margins since last 3-months.

Sarepta Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.65 - a -193.3% fall from last quarter’s estimates.

Sarepta Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.65.

Sarepta Therapeutics, Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Sarepta Therapeutics, Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.